Allogene Therapeutics Inc
ALLOLatest QuantConomy context for ALLO: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Allogene Therapeutics Inc
Allogene Therapeutics Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company is dedicated to pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for the treatment of cancer and autoimmune diseases. Allogene's product pipeline includes several "off-the-shelf" CAR T cell candidates, such as ALLO-501, ALLO-501A, and ALLO-316, which are designed to treat blood cancers, solid tumors, and autoimmune diseases. The company's mission is to create and lead the next revolution in cell therapy by delivering these innovative products to patients, leveraging advanced gene-engineering, gene-editing, and proprietary lymphodepletion technologies. Allogene is led by a highly experienced management team with a strong track record in cell therapy and oncology drug development.
- Symbol
- ALLO
- Name
- Allogene Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alpaca alphavantage fmp sec nasdaq
Recent signals for ALLO
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| operating income change | very bullish | 76 | May 13, 12:00 AM | ALLO (Q1 2026, operating income): grew 78.0% (-$209.31M → -$46.09M). [sequential period basis, very bullish signal] |
| net income change | very bullish | 76 | May 13, 12:00 AM | ALLO (Q1 2026, net income): grew 77.7% (-$190.89M → -$42.61M). [sequential period basis, very bullish signal] |
| eps change | very bullish | 76 | May 13, 12:00 AM | ALLO (Q1 2026, diluted eps): EPS grew 79.3% ($-0.87 → $-0.18). [sequential period basis, very bullish signal] |
FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| ALLO | NASDAQ | alpaca | Allogene Therapeutics, Inc. Common Stock |
| ALLO | NASDAQ | alphavantage | Allogene Therapeutics Inc |
| ALLO | NASDAQ | fmp | Allogene Therapeutics, Inc. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Roberts Zachary | President and CEO | grant | 134,530 | — | — | 4 on EDGAR |
| Jun 18, 2026 | Barrett Elizabeth A. | Insider | grant | 95,400 | — | — | 4 on EDGAR |
| Jun 18, 2026 | Mayo Stephen | Insider | grant | 144,400 | — | — | 4 on EDGAR |
| Jun 18, 2026 | MESSEMER DEBORAH M. | Insider | grant | 95,400 | — | — | 4 on EDGAR |
| Jun 18, 2026 | WITTE OWEN N. | Insider | grant | 95,400 | — | — | 4 on EDGAR |
| Jun 18, 2026 | Humer Franz B | Insider | grant | 95,400 | — | — | 4 on EDGAR |
| Jun 18, 2026 | SATO VICKI L | Insider | grant | 95,400 | — | — | 4 on EDGAR |
| Jun 18, 2026 | Kazam Joshua A | Insider | exercise | 47,700 | $0.00 | $0 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query ALLO context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access